Summary
Vertex Pharmaceuticals Inc. (VRTX) issued an 8-K filing on October 24, 2019, to provide an update on preclinical data for its APOL1-mediated kidney disease program, specifically concerning the lead development candidate, VX-147. The company identified discrepancies in a specific set of preclinical mouse model data previously disclosed in July 2019, rendering that particular dataset unreliable. This has led Vertex to disqualify this single data set from further consideration. Importantly, the company has re-verified data from five other preclinical efficacy studies supporting VX-147's development, and the preclinical safety data package remains unaffected. Vertex has notified the FDA, which supports the continuation of the VX-147 clinical development program without changes.
Key Highlights
- 1Vertex identified discrepancies in a specific preclinical mouse data set for VX-147, leading to its disqualification.
- 2The company has re-verified five other preclinical efficacy studies supporting VX-147's development.
- 3The preclinical safety data package for VX-147 is unaffected by the data discrepancy.
- 4The FDA has been notified and supports Vertex's plan to continue the VX-147 clinical development program unchanged.
- 5The Phase 1 clinical trial for VX-147 is ongoing and on track for completion in Q4 2019.
- 6Vertex plans to initiate a Phase 2 trial in 2020 if Phase 1 results are positive, focusing on reducing urine protein levels in FSGS patients.
- 7Vertex continues to advance other APOL1 inhibitors through preclinical development.